The Cooper Companies, Inc. · NASDAQ (us_market)
Healthcare · Medical Instruments & Supplies · United States
The Cooper Companies, Inc., together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment offers spherical, toric, and multifocal contact lenses that address vision challenges, such as astigmatism, presbyopia, and myopia. Its CooperSurgical segment focuses on family and women's health care, which provides fertility products and services, medical devices, and contraception, as well as cryostorage, such as cord blood and cord tissue storage. This segment offers Paragard, a hormone-free intrauterine device; and fertility consumables and equipment, donor gamete services, and genomic services, including genetic testing. The company sells its products to distributors, group purchasing organizations, eye care and health care professionals, including independent practices, corporate retailers, hospitals and clinics, and authorized resellers. The Cooper Companies, Inc. was founded in 1958 and is headquartered in San Ramon, California.
| Event Period | Drawdown | Buy Point (Bottom) | Sell Point (Peak) | ticker.setupCols.buyScore | ticker.setupCols.sellScore | Max Return | Algo Return |
|---|---|---|---|---|---|---|---|
DROP2025-05-12$84.44 RISE2025-09-17$64.32 PEAK2025-12-11$82.11 213d | -23.8% 128d | Missed | Missed | — | — | +27.7% 85d | Missed |
DROP2024-12-04$104.98 RISE2025-04-08$71.50 PEAK2025-05-12$84.44 159d | -31.9% 125d | Missed | Missed | — | — | +18.1% 34d | Missed |
DROP2024-03-04$102.77 RISE2024-07-03$85.51 PEAK2024-09-16$111.23 196d | -16.8% 121d | Missed | Missed | — | — | +30.1% 75d | Missed |
DROP2023-07-14$99.34 RISE2023-10-27$76.72 PEAK2024-01-22$97.00 192d | -22.8% 105d | Missed | Missed | — | — | +26.4% 87d | Missed |
DROP2022-06-07$86.88 RISE2022-10-14$62.17 PEAK2023-01-11$87.58 218d | -28.4% 129d | 2022-07-13 $73.04 | 2023-01-11 $87.58 | 90Quality on Sale | 61Watch | +40.9% 89d | +19.9% Held 182d |
DROP2022-04-01$107.11 RISE2022-07-14$72.13 PEAK2022-08-16$84.32 137d | -32.7% 104d | 2022-07-13 $73.04 | 2022-08-16 $84.32 | 90Quality on Sale | 85Deep Value | +16.9% 33d | +15.4% Held 34d |
DROP2020-02-21$88.92 RISE2020-06-29$67.73 PEAK2020-09-17$86.95 209d | -23.8% 129d | Missed | Missed | — | — | +28.4% 80d | Missed |
DROP2020-01-22$90.00 RISE2020-03-23$60.86 PEAK2020-06-08$80.07 138d | -32.4% 61d | Missed | Missed | — | — | +31.6% 77d | Missed |
Personal health and wellness is one of the many secular tailwinds for healthcare companies. But financial performance has lagged recently as players offloaded surplus COVID inventories in 2023 and 2024, a headwind for overall demand. The result? Over the past six months, the industry’s 4.1% return has trailed the S&P 500 by 6.2 percentage points.
Are Wall Street analysts favoring medical device company The Cooper Companies?
Are Wall Street analysts favoring medical device company The Cooper Companies?
Generation IM Q1 2026 13F: portfolio drops to $11.16B; top holdings MSFT, AMZN & GOOGL; big buys/sells and new picks.
Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the many opportunities in front of them attract significant competition, spanning from industry behemoths with seemingly infinite resources to small, nimble players with chips on their shoulders.
Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the many opportunities in front of them attract significant competition, spanning from industry behemoths with seemingly infinite resources to small, nimble players with chips on their shoulders.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
- 13F Filing
Are you wondering if Cooper Companies at around US$59.47 is starting to look interesting on valuation, or if the recent weakness is a warning sign you should not ignore? The stock is down 2.7% over the last week, 17.1% over the last month, and 26.1% over the past year. This has shifted the conversation toward whether the current price reflects higher risk, potential value, or a mix of both. Recent coverage has focused on the stock’s sustained share price pressure and what it might say about...
Are you wondering if Cooper Companies at around US$59.47 is starting to look interesting on valuation, or if the recent weakness is a warning sign you should not ignore? The stock is down 2.7% over the last week, 17.1% over the last month, and 26.1% over the past year. This has shifted the conversation toward whether the current price reflects higher risk, potential value, or a mix of both. Recent coverage has focused on the stock’s sustained share price pressure and what it might say about...
Clene (CLNN) delivered earnings and revenue surprises of +38.00% and -62.50%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Clene (CLNN) delivered earnings and revenue surprises of +38.00% and -62.50%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
By Karen Roman National Vision Holdings, Inc. (Nasdaq: EYE) said first quarter revenue increased 6.6% to $543.9 million compared to the year prior. Adjusted earnings per share rose to $0.45 compared to $0.34 the previous year, and the company confirmed its 2026 fiscal guidance. “We believe our advancements across merchandising and store experience are strengthening […]
By Karen Roman National Vision Holdings, Inc. (Nasdaq: EYE) said first quarter revenue increased 6.6% to $543.9 million compared to the year prior. Adjusted earnings per share rose to $0.45 compared to $0.34 the previous year, and the company confirmed its 2026 fiscal guidance. “We believe our advancements across merchandising and store experience are strengthening […]
Staar Surgical (STAA) delivered earnings and revenue surprises of +192.31% and +1.88%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Staar Surgical (STAA) delivered earnings and revenue surprises of +192.31% and +1.88%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all large-cap stocks are created equal - some are struggling with slowing growth, declining margins, or increased competition.
The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all large-cap stocks are created equal - some are struggling with slowing growth, declining margins, or increased competition.
Dentsply (XRAY) delivered earnings and revenue surprises of -3.95% and +5.12%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| COO | -1.84% | -27.06% | -25.32% | -10.35% |
| XLV | +2.97% | -5.72% | -3.44% | +12.69% |
| Alpha (stock − sector) | -4.81% | -21.35% | -21.87% | -23.04% |
| Filed | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-04-21 | Rosebrough Walter M Jr | Director | M Option exercise(deriv) | 832 | — | +$0 |
| 2026-04-21 | Rosebrough Walter M Jr | Director | A Grant / award(deriv) | 832 | — | +$0 |
| 2026-04-21 | Rosebrough Walter M Jr | Director | M Option exercise | 832 | — | +$0 |
| 2026-04-06 | Kurzius Lawrence Erik | Director | A Grant / award(deriv) | 3,779 | — | +$0 |
| 2026-04-06 | Kurzius Lawrence Erik | Director | M Option exercise(deriv) | 3,322 | — | +$0 |
| 2026-04-06 | Kurzius Lawrence Erik | Director | M Option exercise | 3,322 | — | +$0 |
| 2026-04-06 | Lucchese Cynthia L | Director | A Grant / award(deriv) | 3,779 | — | +$0 |
| 2026-04-06 | Lucchese Cynthia L | Director | M Option exercise(deriv) | 3,322 | — | +$0 |
| 2026-04-06 | Lucchese Cynthia L | Director | M Option exercise | 3,322 | — | +$0 |
| 2026-04-06 | MADDEN TERESA S | Director | A Grant / award(deriv) | 3,779 | — | +$0 |
| 2026-04-06 | MADDEN TERESA S | Director | M Option exercise(deriv) | 3,322 | — | +$0 |
| 2026-04-06 | MADDEN TERESA S | Director | M Option exercise | 3,322 | — | +$0 |
| 2026-04-06 | Rosebrough Walter M Jr | Director | A Grant / award(deriv) | 3,779 | — | +$0 |
| 2026-04-06 | Carbone Barbara | Director | A Grant / award(deriv) | 3,779 | — | +$0 |
| 2026-04-06 | Carbone Barbara | Director | M Option exercise(deriv) | 3,050 | — | +$0 |
| 2026-04-06 | Carbone Barbara | Director | M Option exercise | 3,050 | — | +$0 |
| 2026-04-06 | Jay Colleen | Director | A Grant / award(deriv) | 4,157 | — | +$0 |
| 2026-04-06 | Jay Colleen | Director | M Option exercise(deriv) | 3,322 | — | +$0 |
| 2026-04-06 | Jay Colleen | Director | M Option exercise | 3,322 | — | +$0 |
| 2026-04-06 | Rivas Maria | Director | A Grant / award(deriv) | 3,779 | — | +$0 |
| 2026-04-06 | Rivas Maria | Director | M Option exercise(deriv) | 3,322 | — | +$0 |
| 2026-04-06 | Rivas Maria | Director | M Option exercise | 3,322 | — | +$0 |
| 2026-04-06 | WEISS ROBERT S | Director | A Grant / award(deriv) | 3,779 | — | +$0 |
| 2026-04-06 | WEISS ROBERT S | Director | M Option exercise(deriv) | 3,654 | — | +$0 |
| 2026-04-06 | WEISS ROBERT S | Director | M Option exercise | 3,654 | — | +$0 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-06-04upcoming | 1.10 | — | — |
| 2026-03-05 | 1.03 | 1.10 | +7.05% |
| 2025-12-04 | 1.11 | 1.15 | +3.29% |
| 2025-08-27 | 1.07 | 1.10 | +3.04% |
| 2025-05-29 | 0.93 | 0.96 | +3.31% |
| 2025-03-06 | 0.91 | 0.92 | +0.93% |
| 2024-12-05 | 1.00 | 1.04 | +4.01% |
| 2024-08-28 | 0.91 | 0.96 | +5.42% |
| 2024-05-30 | 0.83 | 0.85 | +2.59% |
| 2024-02-29 | 0.78 | 0.85 | +8.47% |
| 2023-12-07 | 0.87 | 0.87 | -0.39% |
| 2023-08-30 | 0.84 | 0.84 | +0.27% |
| 2023-06-01 | 0.76 | 0.77 | +1.69% |
| 2023-03-02 | 0.67 | 0.73 | +7.45% |
| 2022-12-08 | 0.78 | 0.69 | -11.64% |
| 2022-08-31 | 0.81 | 0.80 | -1.18% |